BioInsights - Robust low-volume production of lipid nanoparticles for nucleic acid drug discovery & screening

Robust low-volume production of lipid nanoparticles for nucleic acid drug discovery & screening

Cell & Gene Therapy Insights 2022; 8(7), 975;

DOI: 10.18609/cgti.2022.143

Published: 14 October 2022
FastFacts
Reka Geczy


Watch the video or read the poster to learn more about: 

  • Generating rapid, reproducible, and small-scale nanoparticle formulations
  • The importance of rapid and low-volume formulations to conserve limited or expensive ingredients
  • A non-turbulent microfluidic mixing technology to produce lipid nanoparticles  on a discovery scale

Reka holds a PhD in Pharmaceutical Sciences from the University of British Columbia with high impact publications at the interface of microfluidics and drug delivery. After her postdoc at the University of Copenhagen, she joined Precision NanoSystems as a Product Development Scientist. Her team is developing potent and efficient lipid nanoparticle compositions for cell therapy, currently focusing on CAR T cancer therapy. Like many teams at Precision NanoSystems, Reka and her team routinely uses the NanoAssemblr® Spark™ to advance early-stage research.